Editas Medicine (EDIT) Revenue (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Revenue of $7.5 million for Q3 2025, up 12265.57% year-over-year from N/an in Q3 2024, and up 110.82% quarter-over-quarter from $3.6 million in Q2 2025.
Editas Medicine (EDIT) Revenue (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Revenue for 11 consecutive years, with $7.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Revenue rose 12265.57% year-over-year to $7.5 million; the TTM figure through Sep 2025 stood at $46.4 million (down 24.9% YoY), while the FY2024 annual figure was $32.3 million, down 58.64% from the prior year.
- Revenue climbed to $7.5 million in Q3 2025 per EDIT's latest filing, from $3.6 million in the prior quarter.
- Across five years, Revenue topped out at $60.0 million in Q4 2023 and bottomed at $42000.0 in Q3 2022.
- Historically, Revenue has averaged $9.0 million across 5 years, with a median of $6.2 million in 2021.
- Annual changes were most pronounced in 2022 — Revenue plunged 99.32% — and 2023, when it jumped 12604.76%.
- Editas Medicine's Revenue stood at $12.5 million in 2021, then plunged by 47.58% to $6.5 million in 2022, then jumped by 818.74% to $60.0 million in 2023, then sank by 49.03% to $30.6 million in 2024, then tumbled by 75.35% to $7.5 million in 2025.
- Business Quant data shows EDIT's Revenue at $7.5 million in Q3 2025, $3.6 million in Q2 2025, and $4.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | 3.58 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Dec 31, 2024 | 30.60 Mn |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 513,000.00 |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 60.05 Mn |
| Sep 30, 2023 | 5.34 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Mar 31, 2023 | 9.85 Mn |
| Dec 31, 2022 | 6.54 Mn |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 6.36 Mn |
| Mar 31, 2022 | 6.77 Mn |
| Dec 31, 2021 | 12.47 Mn |
| Sep 30, 2021 | 6.20 Mn |
| Jun 30, 2021 | 379,000.00 |
| Mar 31, 2021 | 6.50 Mn |
| Dec 31, 2020 | 11.42 Mn |